M.D. Anderson Cancer Center — CureCurrent

How to interpret these research links

Connected source records

The exact organization name M.D. Anderson Cancer Center appears in 737 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials737

Recruiting shown60

Roles2

SourceClinicalTrials.gov

Clinical trials

60 shown

Prediction Of Lymphedema In Patients With Inflammatory BreastCancer Using Preoperative Bioimpedance MeasurementsNCT07855627 · lead sponsor · 2026-09-16

Group-based Comprehensive Lifestyle Program for Women With Metastatic Breast CancerNCT07179809 · lead sponsor · 2026-08-21

Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung CancerNCT07579221 · lead sponsor · 2026-07-16

Efforts to Increase Representation in Prostate Cancer Clinical Trials at Lyndon B. Johnson HospitalNCT07591701 · lead sponsor · 2026-05-26

Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A TrialNCT07382726 · lead sponsor · 2026-05-15

Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung CancerNCT07415005 · lead sponsor · 2026-04-24

Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigating Radiation-response and ToxicityNCT06909201 · lead sponsor · 2026-03-31

NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung CancerNCT07224152 · lead sponsor · 2026-03-27

Pilot Study of Aerobic Exercise During Immune Checkpoint Inhibitor Therapy in Early-Stage TNBCNCT07216495 · lead sponsor · 2026-02-23

Decision Support Tool to Enhance Germline Genetic Testing for Patients With Prostate CancerNCT07377006 · lead sponsor · 2026-02-02

Together Stronger: A Family-centered Lifestyle Intervention for Black Prostate Cancer Survivors and Their CaregiversNCT07164456 · lead sponsor · 2026-01-13

A Prospective Single Center, Single Arm, Single-institution Registry That Aims to Assess the Safety and Quality of Life Benefits of Computer-assisted Vacuum Thrombectomy (CAVT) in the Treatment of Cancer Patients With Intermediate Risk Pulmonary Embolism (PE)NCT07298096 · lead sponsor · 2026-01-08

A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung CancerNCT07133425 · lead sponsor · 2025-11-06

Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR TrialNCT07407920 · lead sponsor · 2025-10-09

Registry Trial and Needs Assessment of Patients With Young-onset Lung Cancer: Impact of a Dedicated Care Program on Patient Experience and OutcomesNCT07220096 · lead sponsor · 2025-09-25

Evaluation of a Novel Optical Microscope With a Deep Depth of Field (DeepDOF) to Provide Histologic-quality Images on Cervical Biopsies and Loop Electrosurgical Excision Procedure (LEEP) Specimens at the Point-of-careNCT06850402 · lead sponsor · 2025-09-22

Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)NCT07011654 · lead sponsor · 2025-09-19

Social and Environmental Determinants of Breast Cancer Survivorship: the Black Breast Cancer Survivor's Intervention (BBCSI)NCT06885203 · lead sponsor · 2025-08-27

Shortening Adjuvant Photon and Proton Irradiation (SAPPHIRe-II): A 4 Cohort, Randomized, Phase II Multi-center Trial Evaluating Shorter Schedules of Adjuvant Regional Nodal Irradiation Among Women and Men With Node-positive and High-risk Node-negative Invasive Breast CancerNCT07076485 · lead sponsor · 2025-08-19

EMERALD: Endocrine Therapy oMission With Radiation in ER+ Breast Cancer: Assessing Quality of Life and Disease Control: a Prospective Phase II TrialNCT06897488 · lead sponsor · 2025-07-17

A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPCNCT06826768 · lead sponsor · 2025-07-09

Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility StudyNCT06759701 · lead sponsor · 2025-07-02

Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate CancerNCT05873192 · lead sponsor · 2025-06-03

Dyadic Yoga Program for Patients Undergoing Thoracic Radiotherapy and Their Family Caregivers: The Testing of a Mobile Application DeliveryNCT06919874 · lead sponsor · 2025-05-14

Multi-center MRD Registry for Inflammatory Breast CancerNCT06966050 · lead sponsor · 2025-05-05

CPRIT: Patient Adherence to Lung Cancer ScreeningNCT06872723 · lead sponsor · 2025-03-21

Bronchoscopic Lung Ablation of Small Thoracic Tumors: the Blastt RegistryNCT06840288 · lead sponsor · 2025-02-19

Novel INPUT Screening Tool to Improve Illness Understanding in Patients With Metastatic or Incurable Lung CancerNCT06743308 · lead sponsor · 2024-12-16

Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell CarcinomaNCT06567314 · lead sponsor · 2024-12-02

Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)NCT06545682 · lead sponsor · 2024-10-15

PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.NCT06274047 · lead sponsor · 2024-09-10

Hyperpolarized 129-Xenon Imaging in Adult Hematopoietic Cell Transplant Recipients With Pulmonary ImpairmentNCT05041140 · lead sponsor · 2024-08-14

PRORAD-5 PROstate RADiation in 5 Fractions: Phase II Five Fraction Radiotherapy for Patients With Advanced Prostate Cancer.NCT06369246 · lead sponsor · 2024-06-27

Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast CancerNCT06318897 · lead sponsor · 2024-05-29

Goals of Care Discussion for Patients With Advanced Lung and Gastrointestinal Cancer in the Emergency Department of a Comprehensive Cancer CenterNCT06420206 · lead sponsor · 2024-05-14

NeoAdjuvant Theranostic Lutetium Study: The Nautilus TrialNCT06066437 · lead sponsor · 2024-03-29

Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)NCT06085729 · lead sponsor · 2024-02-29

Surveillance MRI Registry for Patients Who Had Breast Cancer With Dense Breast TissueNCT06127797 · lead sponsor · 2024-01-11

A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical ProstatectomyNCT06085664 · lead sponsor · 2023-12-04

Opioid-Sparing Effects of Nurse-Delivered Hypnosis During Breast Cancer SurgeryNCT05766891 · lead sponsor · 2023-10-12

Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast CancerNCT05406232 · lead sponsor · 2023-09-15

Older Men's Decision Making About Active Surveillance for Prostate Cancer - Aim 3: Decision Aid Efficacy TestingNCT06785441 · lead sponsor · 2023-05-25

Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid MalignanciesNCT05039632 · lead sponsor · 2023-05-08

Trial Of PreoperAtive Radiation (TOPAz): A Randomized Trial Comparing Hypofractionated Versus Conventionally Fractionated Preoperative Radiation Followed by Mastectomy With Immediate Autologous Breast Reconstruction With Integrated Tissue Nanomechanical Phenotype EvaluationNCT05774678 · lead sponsor · 2023-04-05

Comprehensive Monitoring of Men With Prostate Cancer Cared for by "Active SurveillanceNCT05840484 · lead sponsor · 2023-03-29

REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)NCT05632809 · lead sponsor · 2023-01-10

The C-MERIT Screening Cohort: Contrast-enhanced Mammography for Breast Cancer Screening and Risk Assessment in Women With Dense BreastsNCT05667532 · lead sponsor · 2022-12-05

Connecting Black Families in Houston, Texas to Hereditary Cancer Genetic Counseling, Genetic Testing, and Cascade Testing by Using a Simple Genetic Risk Screening Tool and TelegeneticsNCT05694559 · lead sponsor · 2022-11-23

Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.NCT05649072 · lead sponsor · 2022-11-18

A Randomized Controlled Trial of Inhaled Tranexamic Acid for the Treatment of Pulmonary Hemorrhage in Cancer PatientsNCT05053867 · lead sponsor · 2022-10-14

Adaptation and Pilot Testing of a Lung Cancer Screening Decision Aid for Patients From a Safety-Net Healthcare SystemNCT07382557 · lead sponsor · 2022-09-29

Older Men's Decision Making About Active Surveillance for Prostate Cancer - Aim 3: Decision Aid Cognitive and Usability TestingNCT05497024 · lead sponsor · 2022-08-15

Utilization of a Peer-Based Approach for the Promotion of Physical Activity in Inactive WomenNCT05053113 · lead sponsor · 2022-07-27

An Evidence-Based Focal Cryotherapy Protocol for Focal Ablation of Intermediate Risk Prostate CancerNCT05454488 · lead sponsor · 2022-07-25

Diagnostic Performance Of Non-Endorectal Coil Multiparametric Magnetic Resonance Imaging Of Prostate With Flexible AIR Coil (DoNEMAC Study)NCT05043012 · lead sponsor · 2022-07-18

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or ThoraxNCT05092373 · lead sponsor · 2022-04-29

Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint InhibitorsNCT04751396 · lead sponsor · 2022-04-20

Comparative Performance of Molecular Breast Imaging (MBI) to Magnetic Resonance Imaging (MRI) of the Breast in Identifying and Excluding Breast Carcinoma in Women at High Risk for Breast CancerNCT05042687 · lead sponsor · 2021-12-13

A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)NCT05035836 · lead sponsor · 2021-11-16

Neutrophil Extracellular Traps Formation in Breast Cancer Patients Taking TamoxifenNCT05056857 · lead sponsor · 2021-10-01

Drugs studied in this sponsor's trials

185 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing M.D. Anderson Cancer Center as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.

carboplatin32

paclitaxel29

cyclophosphamide21

docetaxel18

cisplatin14

prednisone12

abiraterone acetate9

capecitabine9

carboplatin RxCUI 40048 · Lead sponsor in 32 linked trial(s) · 3 currently recruiting 32 trials paclitaxel RxCUI 56946 · Lead sponsor in 28 linked trial(s) · 2 currently recruiting 29 trials cyclophosphamide RxCUI 3002 · Lead sponsor in 19 linked trial(s) · 2 currently recruiting 21 trials docetaxel RxCUI 72962 · Lead sponsor in 18 linked trial(s) · 0 currently recruiting 18 trials cisplatin RxCUI 2555 · Lead sponsor in 13 linked trial(s) · 0 currently recruiting 14 trials prednisone RxCUI 8640 · Lead sponsor in 12 linked trial(s) · 2 currently recruiting 12 trials abiraterone acetate RxCUI 1100071 · Lead sponsor in 9 linked trial(s) · 1 currently recruiting 9 trials capecitabine RxCUI 194000 · Lead sponsor in 9 linked trial(s) · 0 currently recruiting 9 trials fluorouracil RxCUI 4492 · Lead sponsor in 9 linked trial(s) · 0 currently recruiting 9 trials pemetrexed RxCUI 68446 · Lead sponsor in 9 linked trial(s) · 1 currently recruiting 9 trials placebo RxCUI 8375 · Lead sponsor in 6 linked trial(s) · 0 currently recruiting 9 trials apalutamide RxCUI 1999574 · Lead sponsor in 8 linked trial(s) · 2 currently recruiting 8 trials dasatinib RxCUI 475342 · Lead sponsor in 7 linked trial(s) · 0 currently recruiting 8 trials doxorubicin RxCUI 3639 · Lead sponsor in 8 linked trial(s) · 1 currently recruiting 8 trials fludarabine RxCUI 24698 · Lead sponsor in 6 linked trial(s) · 1 currently recruiting 8 trials bevacizumab RxCUI 253337 · Lead sponsor in 7 linked trial(s) · 0 currently recruiting 7 trials epirubicin RxCUI 3995 · Lead sponsor in 7 linked trial(s) · 0 currently recruiting 7 trials erlotinib RxCUI 337525 · Lead sponsor in 7 linked trial(s) · 0 currently recruiting 7 trials etoposide RxCUI 4179 · Lead sponsor in 7 linked trial(s) · 0 currently recruiting 7 trials imatinib mesylate RxCUI 284924 · Lead sponsor in 7 linked trial(s) · 0 currently recruiting 7 trials olaparib RxCUI 1597582 · Lead sponsor in 7 linked trial(s) · 1 currently recruiting 7 trials doxorubicin hydrochloride RxCUI 142433 · Lead sponsor in 6 linked trial(s) · 0 currently recruiting 6 trials ipilimumab RxCUI 1094833 · Lead sponsor in 4 linked trial(s) · 0 currently recruiting 6 trials cabazitaxel RxCUI 996051 · Lead sponsor in 5 linked trial(s) · 1 currently recruiting 5 trials

Sponsor roles

lead sponsor661

collaborator76

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.